Data from a new study led by University of Kentucky Markey Cancer Center researchers shows that repurposing drugs used to treat leukemia has promise for preventing melanoma metastasis.
The study showed new evidence linking the activation of ABL kinases – cancer-promoting genes – to the secretion of pro-metastatic cathepsins in melanoma. Cathepsins are enzymes that degrade proteins and are highly expressed in cancer cells, resulting in their release into the environment between the cells. These enzymes "chew up" the fibrous matrix around tumors, which allows them to get into the blood stream and lymphatic system and spread around the body.
Their work showed that ABL kinases induce cathepsin expression and secretion by increasing the activity of key transcription factors that upregulate numerous proteins involved in metastasis. Transcription factors bind to the regulatory part of genes and induce their expression. This study is the first to demonstrate that ABL kinases not only increase the abundance of the transcription factors, but also regulate the ability of these transcription factors to bind to the promoters and induce gene expression.
Lastly, the researchers found that ABL kinases inhibitors already approved by the Food & Drug Administration (FDA) for treating leukemia also prevented metastasis induced by secreted cathepsins in animal models of metastatic melanoma.
"These data have important therapeutic implications, as drugs that inhibit ABL kinases have been used for decades to treat leukemia with few side effects," said Rakshamani Tripathi, postdoctoral scholar in the UK Department of Pharmacology and Nutritional Sciences and lead author on the study. "Repurposing these drugs may represent a new strategy for targeting cathepsins and may be an effective approach for treating metastatic melanoma patients."
The number of new cases of melanoma, as well as melanoma death rates, have increased steadily for the past 30 years in the United States. Metastasis to distant organ sites such as the lung, liver brain and bone is the major cause of melanoma-related deaths. Despite new advances in metastatic melanoma treatment, the 5-year survival rate is only 15 to 20 percent.
Feature Courtesy of the University of Kentucky Markey Cancer Center